Skip to main content

Aprea Therapeutics, Inc.

APRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001781983

No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Aprea Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Aprea Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Aprea Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Henneman John B IIIDirector13,364Jun 17, 20261
Bizzari Jean-PierreDirector4,180Jun 17, 20261
Peters RichardDirector6,254Jun 17, 20262
Grissinger MichaelDirector6,024Jun 17, 20261
Seizinger Bernd R.Director48,910Jun 17, 20261
Gruia GabrielaDirector4,180Jun 17, 20261
Duey MarcDirector259,290Jun 17, 20262
Pamukcu RifatDirector8,581Jun 17, 20261
Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr43,528Apr 1, 20264
Gilad OrenPresident/CEO393,895Mar 16, 20263
Mirza Nadeem Q.Chief Medical Officer6,730May 2, 20240
Schade Christian SDirector259,246Aug 1, 20220
Coiante Scott MSVP, Chief Financial Officer145,065Aug 1, 20220
Korbel Gregory AlanSVP, Chief Operating Officer45,762Aug 1, 20220
Attar Eyal C.SVP, Chief Medical Officer57,233Jun 7, 20220
Abrahmsen Lars B.SVP, Chief Scientific Officer43,700Mar 14, 20220
Kelly Michael AaronDirector4,610Jul 1, 20210
Namouni FouadDirector4,610Jul 1, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 1, 2026 (view filing)Mar 311 dayHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+62.0K$0.81+$25.1K–31.0K afterDerivative2 lots
Apr 1, 2026 (view filing)Mar 311 dayPeters RichardDirectorPPurchase+247.8K$0.81+$100.4K–123.9K afterDerivative2 lots
Feb 2, 2026 (view filing)Jan 303 daysGilad OrenPresident/CEOPPurchase+28.1K$0.89+$25.0K+8.1%373.7K after
Feb 2, 2026 (view filing)Jan 303 daysGilad OrenPresident/CEOPPurchase+28.1K–––28.1K afterDerivative
Feb 2, 2026 (view filing)Jan 303 daysHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+5.70K$0.89+$5.07K+20.6%33.4K after
Feb 2, 2026 (view filing)Jan 303 daysHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+5.70K–––5.70K afterDerivative
Dec 11, 2025 (view filing)Dec 101 dayDuey MarcDirectorPPurchase+21.5K$1.17+$25.1K+9.1%256.2K after
Dec 11, 2025 (view filing)Dec 101 dayDuey MarcDirectorPPurchase+21.5K–––21.5K afterDerivative
Dec 11, 2025 (view filing)Dec 101 dayHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+5.00K$1.17+$5.85K+22.0%27.7K after
Dec 11, 2025 (view filing)Dec 101 dayHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+5.00K–––5.00K afterDerivative
Dec 11, 2025 (view filing)Dec 101 dayGilad OrenPresident/CEOPPurchase+42.9K$1.17+$25.1K–21.5K afterDerivative2 lots
Apr 4, 2025 (view filing)Apr 31 dayGilad OrenPresident/CEOPPurchase+5.50K$1.84+$10.1K+1.6%345.6K after2 lots
Oct 25, 2024 (view filing)Oct 187 daysLateDuey MarcDirectorSSale−6.46K$4.58−$29.6K−2.7%233.7K after
Oct 24, 2024 (view filing)Oct 231 dayGilad OrenPresident/CEOPPurchase+500$3.92+$1.96K+0.2%333.4K after
Oct 17, 2024 (view filing)Oct 161 dayDuey MarcDirectorPPurchase+30.0K$4.39+$131.7K+14.3%240.1K after
Oct 16, 2024 (view filing)Oct 151 dayGilad OrenPresident/CEOPPurchase+250$2.90+$725+0.1%332.9K after
Oct 16, 2024 (view filing)Oct 142 daysDuey MarcDirectorPPurchase+190$2.58+$490.2+0.1%210.1K after
Oct 16, 2024 (view filing)Oct 115 daysHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+50$2.46+$123+0.3%19.4K after
Oct 15, 2024 (view filing)Oct 114 daysSeizinger Bernd R.DirectorPPurchase+10.0K$2.68+$26.8K+28.8%44.7K after
Oct 15, 2024 (view filing)Oct 10-145 daysGilad OrenPresident/CEOPPurchase+1.15K$2.58+$2.97K+0.3%332.6K after2 lots
Oct 15, 2024 (view filing)Oct 105 daysHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+450$2.61+$1.17K+2.4%19.3K after
Mar 14, 2024 (view filing)Mar 131 dayHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+1.01K$7.29+$7.36K+7.0%15.5K after
Mar 14, 2024 (view filing)Mar 131 dayHamill John P.SrVP/CFO/Prin Fin & Acct OfcrPPurchase+1.01K–––505 afterDerivative2 lots
Mar 14, 2024 (view filing)Mar 131 daySeizinger Bernd R.DirectorPPurchase+6.86K$7.29+$50.0K+25.6%33.7K after
Mar 14, 2024 (view filing)Mar 131 daySeizinger Bernd R.DirectorPPurchase+6.86K–––3.43K afterDerivative2 lots
Mar 14, 2024 (view filing)Mar 131 dayHenneman John B IIIDirectorPPurchase+6.86K$7.29+$50.0K+536.4%8.14K after
Mar 14, 2024 (view filing)Mar 131 dayHenneman John B IIIDirectorPPurchase+6.86K–––3.43K afterDerivative2 lots
Mar 14, 2024 (view filing)Mar 131 dayGilad OrenPresident, CEOPPurchase+2.00K$7.29+$14.6K+0.6%324.8K after
Mar 14, 2024 (view filing)Mar 131 dayGilad OrenPresident, CEOPPurchase+2.00K–––1.00K afterDerivative2 lots
Jun 8, 2023 (view filing)Jun 6-72 daysSeizinger Bernd R.DirectorPPurchase+10.1K$3.66+$37.0K+62.2%26.3K after2 lots
May 19, 2022 (view filing)May 181 daySeizinger Bernd R.DirectorPPurchase+50.0K$0.71+$35.5K+18.6%318.6K after
May 19, 2022 (view filing)May 181 daySchade Christian SChairman & CEOPPurchase+37.5K$0.64+$24.0K+14.7%292.6K after
Mar 1, 2022 (view filing)Feb 281 dayAttar Eyal C.SVP, Chief Medical OfficerSSale−36.0K$1.73−$62.3K−43.4%47.0K after
Dec 3, 2021 (view filing)Dec 12 daysKorbel Gregory AlanSVP, Chief Business OfficerSSale−27.5K$3.96−$108.9K−61.6%17.2K after
Nov 3, 2021 (view filing)Nov 12 daysKorbel Gregory AlanSVP, Chief Business OfficerSSale−27.5K$5.00−$137.5K−61.6%17.2K after
Oct 5, 2021 (view filing)Oct 14 daysAbrahmsen Lars B.SVP, Chief Scientific OfficerSSale−50.0K$4.89−$244.5K−72.5%19.0K after
Oct 5, 2021 (view filing)Oct 14 daysKorbel Gregory AlanSVP, Chief Business OfficerSSale−27.5K$4.89−$134.5K−61.6%17.2K after
Sep 22, 2021 (view filing)Sep 202 daysKorbel Gregory AlanSVP, Chief Business OfficerSSale−33.0K$4.97−$163.9K−65.8%17.2K after2 lots
Sep 22, 2021 (view filing)Sep 202 daysAbrahmsen Lars B.SVP, Chief Scientific OfficerSSale−25.0K$4.97−$124.3K−56.8%19.0K after
Sep 20, 2021 (view filing)Sep 164 daysAttar Eyal C.SVP, Chief Medical OfficerSSale−16.0K$4.68−$74.7K−16.1%83.0K after